Support
Login

Our mission

At Echo IQ, we use the AI-powered technology in EchoSolv to enhance the diagnosis of structural heart disease. Our mission is to help improve the lives of people by supporting earlier, more accurate detection of a number of life-threatening but often treatable conditions.

The Echo IQ platform applies innovative methodologies and a proprietary algorithm to produce risk assessments for patients using their echocardiographic measurements. We harness the power of AI to produce consistent outputs at speed, and without bias. Applied to the identification of aortic stenosis, for example, EchoSolv has been designed to identify patients at risk of mortality who might benefit from further clinical review. We are proud to be applying leading-edge technologies, led by thought-leaders in cardiology, to deliver new solutions in cardiac care.

Our values

Innovation. We embrace smart ways of doing things, encouraging creativity and harnessing cutting-edge medical technology.

Quality. We place quality and scientific rigour at the heart of everything we do.

Performance. We strive for superior business results and push ourselves to become industry leaders through our high-tech diagnostic solutions.

Health and well-being. We cultivate a positive environment for our people, and through life-enhancing technology solutions. Our technology aims to save lives.
Partnership. We focus on fostering a collaborative spirit with all our stakeholders, clients, employees and service provider

Our leadership team

Dustin Haines

Chief Executive Officer

Sam Dribin

Chief Technology Officer

Deon Strydom

Chief Commercial Officer

Dane Brescacin

VP Regulatory Affairs

Don Fowler

President, Echo IQ USA

Specialist advisors

Prof. Geoff Strange

Advisor

Prof. David Playford

Advisor

Advisory board

Huon H. Gray

CBE MD FRCP FESC MACC

Madeline Jankowski

BS ACS RDCS FASE

Hashim A. Khan

MD FACC

Michael J. Mack

MD MACC

David Ouyang

MD FACC FASE

Jordan B. Strom

MD MSc FACC FASE

James D. Thomas

MD FACC FASE FESC

Board of directors

Andrew Grover

Executive Chairman

Jessamyn Lyons

Company Secretary

Steven Formica

Non-Executive Director

Steve Picton

Non-Executive Director

Ken Nelson

Ken Nelson

Non-Executive Director

Our partners

Cassling
StudyCast
Hydrix
Piccolo
Medaxiom
Extential

Dustin Haines

Chief Executive Officer Dustin Haines brings 25 years’ experience in leading global businesses in pharmaceuticals, biotechnology, and medical devices. Most recently, Mr. Haines was head of Asia, Middle East, Turkey, and Russia for Gilead Sciences where he managed over $1.2B in revenue. As a leader, Mr. Haines has launched innovative technologies globally with extensive experience in regulatory approvals, reimbursement, commercialization, and scaling business.

Close

Sam Dribin

Sam Dribin is a seasoned Chief Technology Officer (CTO) with deep expertise in biotech software development, AI, DevOps, and cloud architecture. With a strong background in building FDA, ISO-13485, and HIPAA-compliant software, Sam specializes in designing secure, scalable, and regulatory-compliant solutions for healthcare and biotech industries.  Sam was the Chief Technology Officer at CureMetrix for nine years, where he oversaw the development and FDA clearances of AI software to help physicians identify breast cancer and arterial calcifications in routine mammograms. Sam has a passion for developing innovative software solutions and has played a key role in the success of previous companies.

Close

Deon Strydom

Deon is an accomplished Chief Commercial Officer with 15 years of experience driving innovation in the Pharmaceutical, Biotechnology, and Medical Device industries. His expertise spans global corporations, early-stage ventures, and startups, where he has successfully led Go-To-Market strategies, strategic partnerships, M&A, licensing, and commercialization efforts. Deon has a proven track record of delivering growth and market expansion across the US, APAC, and EU.

Close

Dane Brescacin

Dane Brescacin is a regulatory affairs and quality specialist with over 15 years of experience in the biotechnology and medical technology industries. With a strong background in regulatory,  quality, and operations, he has successfully led global regulatory strategies, securing FDA clearances, CE Marks, and TGA approvals. Dane has a deep understanding of international regulatory frameworks across different clinical indications and technologies and has guided cross-functional teams through complex submission processes to ensure compliance and market access.

Close

Don Fowler

Don Fowler is an accomplished senior executive with over 40 years of experience in the healthcare industry, specializing in strategic growth, sales leadership, and business transformation. Previously, Don was the CEO of Toshiba America Medical Systems and also held senior executive positions at Siemens Healthcare, overseeing multi-billion-dollar sales budgets, P&L’s, global marketing strategies, and high -performing teams. His expertise spans executive leadership, financial management, board governance and business development. With a strong track record in driving innovation and market expansion, he continues to influence the healthcare and technology sectors.

Close

Huon H. Gray

Huon Gray was consultant adult and interventional cardiologist at Southampton University Hospital from 1989 to 2020. In 2003 he was appointed President of the British Cardiac Society, receiving its Mackenzie Medal in 2014.

Prof. Gray co-chaired the Dept. of Health’s National Infarct Angioplasty Project (2006-8), which led to the subsequent national roll out of primary PCI for ST elevation myocardial infarction in England. He was also clinical adviser and then chair of two NICE guidelines on acute coronary syndromes (2007-13).

He is honorary professor at Queen Mary University, London and has published widely on various aspects of cardiology and health service delivery. He was Deputy and then Interim National Clinical Director for Heart Disease at the United Kingdom’s Department of Health (2007-12), co-producing its CVD Outcomes Strategy (2013), and was then National Clinical Director for Heart Disease in NHS England between 2013-19, helping develop the CVD priorities in the NHS Long Term Plan (2019). He was made Commander of the Excellent Order of the British Empire (CBE) in the Queen’s New Year’s Honours list 2019.

Huon has served in various capacities within the American College of Cardiology (ACC); as chair of its International Council (2008-13), on its Board of Trustees (2012-16), as member of its Governance Committee (2016-19) and then its chair (2019-22). He received the ACC’s Presidential Citation in 2013 and designation as Master of the ACC in 2018.

Close

Madeline Jankowski

Madeline Jankowski is an advanced cardiac sonographer and echocardiography research associate at Northwestern University in Chicago, IL. In clinical practice, she focuses on complex valve disease for research trials, hemodynamic stress echocardiography, and advanced imaging tools such as global longitudinal strain imaging and 3D echocardiography. Her research efforts focus on advanced echocardiography tools and integration of artificial intelligence into echocardiography.

Growing up in the Midwest, Madeline went to ultrasound school in Sioux Falls, SD and clinical internship at Duke University in Durham, NC before beginning her sonographer practice at Cleveland Clinic in Cleveland, OH. She joined Northwestern Medicine in 2014 as a Lead Cardiac Sonographer and has recently moved into a more research-focused role with Northwestern University.

Madeline has been an active lecturer and volunteer for the field of echocardiography – educating, representing and advocating for sonographers since 2014. She has been invited faculty for many conferences including: the American Society of Echocardiography (ASE) Scientific Sessions, ASE’s Echo Hawaii, Echo Northwestern, and the American College of Cardiology (ACC) Scientific Sessions. She is currently in the 2nd cohort of the ASE Leadership Academy with expected graduation in June 2022. Madeline also volunteers for American Registry for Diagnostic Medical Sonography (ARDMS) and currently holds the position of Chair for the Adult Echo Boards Exam Committee.

Close

Hashim A. Khan

Dr. Khan is a practicing interventional cardiologist at the renowned San Diego Cardiac Center in San Diego, California. He obtained a B.Sc. in Cell and Structural Biology from the University of Illinois in Urbana Champaign, and his Medical Doctorate at Northwestern University in Chicago, IL. Dr. Khan then completed his residency in Internal Medicine at Northwestern University after which he pursued fellowship training in cardiovascular diseases at the Scripps Clinic in La Jolla, CA. Dr. Khan culminated his training with an advanced fellowship in interventional and structural cardiology at Northwestern University. During his tenure as a resident and fellow, Dr. Khan was awarded several teaching awards as well as research awards. His research interests were primarily in the field of echocardiography as it applies to the exciting and evolving field of structural interventions in cardiology. Dr. Khan is board certified in Cardiovascular Diseases, Interventional Cardiology, Echocardiography, Nuclear Cardiology and Internal Medicine.

Dr. Khan is a Clinical Scholar and engages in Cardiovascular research at the Scripps Translational Science Institute. He has a progressive approach to adopting newer, more successful therapies based on clinical research and frequently delivers ground-breaking treatments in advance of other heart clinics. Dr. Khan is actively engaged in clinical medicine and is especially devoted to the echocardiography laboratory and the role it plays in his ability to perform interventions designed to treat valvular heart disease in a minimally invasive manner. Dr. Khan performs TAVR and Mitraclip procedures frequently and is acutely aware of the importance a timely diagnosis makes in improving the prognosis of valvular heart disease for a patient.

Dr. Khan has dedicated his life to treating a range of heart conditions and researching new medical approaches to heart diseases and conditions. He is progressive in adopting newer, more successful therapies based on clinical research and frequently delivers ground-breaking treatments to his patients.

Close

Michael J. Mack

Dr. Michael Mack has practiced cardiothoracic surgery in Dallas, TX since 1982. He is board certified in Internal Medicine, General Surgery, and Thoracic Surgery and is currently the Director of the Cardiovascular Service Line for Baylor Scott & White Health, Chair of the Baylor Scott & White Cardiovascular Governance Council and Past President of the Baylor Scott & White Research Institute. He has over 850 peer reviewed publications.

Dr. Mack is also the Senior Vice Chair of the Cardiothoracic Surgery Network (CTSN) of the NIH and is an Associate Editor of the Journal of American College of Cardiology. He is a Director of the American Board of Thoracic Surgery, Co-Chair of the Heart Valve Collaboratory and a member of the ACC Innovations Work Group. Dr. Mack was President of the Society of Thoracic Surgeons (STS) 2011 and is Past President of the Thoracic Surgery Foundation for Research and Education (TSFRE) 2009-2011, the Southern Thoracic Surgical Association (STSA) 2009 and the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2000. He is also a past member of the American College of Cardiology Board of Trustees, Nominating Committee, and Governance Committee and is the past Co-Chair of the STS/ACC National Transcatheter Valve Therapy (TVT) Registry Stakeholder Advisory Group.

He is a Master of the ACC and is an honorary member of the German Society for Thoracic and Cardiovascular Surgery and the Indian Association of Cardiovascular and Thoracic Surgery, Mexican Society of Cardiac Surgery and has received the Presidential Citation of the American College of Cardiology and the Transcatheter Cardiovascular Therapeutics (TCT) Lifetime Achievement Award.

Close

David Ouyang

Dr. David Ouyang is a Los Angeles based cardiologist affiliated with the internationally recognised Cedars-Sinai Medical Center. He obtained his medical degree from the University of California (San Francisco) School of Medicine, residency and fellowship in Cardiovascular Medicine at Stanford University, and is Board Certified in Cardiovascular Disease and Internal Medicine. Dr. Ouyang has also completed post-doctoral studies in Computer Science and Biomedical Data Science at Stanford University.

Having majored in Statistics (Rice University), Dr. Ouyang has always been fascinated by how to visualise and interpret data. He believes strongly in the opportunity to apply increases in data being collected to personalise care and improve diagnosis and treatment of cardiovascular disease.

Dr. Ouyang was a competition finalist in the American Society of Echocardiography Arthur Weyman Young Investigator’s Award Competition and was awarded the 2018 Merck Research Fellowship at the American College of Cardiology Foundation. He received the Edwin Alderman Award for Excellence in Clinical Research in 2020. Expert in the statistical analysis of large datasets within cardiovascular medicine, he has produced a significant number of research publications that address deep learning and computer vision of cardiovascular imaging.

Close

Jordan B. Strom

Dr. Jordan Strom is Associate Director of the Echocardiography Laboratory and Director of Echocardiographic Research at Beth Israel Deaconess Medical Center, Section Head of Cardiovascular Imaging Research at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, and Assistant Professor of Medicine at Harvard Medical School.

He received his B.S. in Biology from Yale University and an M.D. from Harvard Medical School, before subsequently training in Internal Medicine at the Massachusetts General Hospital and in Cardiovascular Medicine at Beth Israel Deaconess Medical Center where he was Chief Fellow for the 2017-2018 year. He received additional post-graduate training in Clinical Epidemiology and Biostatistics at the Harvard T.H. Chan School of Public Health, receiving an M.Sc. in Epidemiology in May 2018. Dr. Strom was the inaugural fellow and is currently a faculty investigator at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology.

His research involves evaluation of the relationship of cardiac structure and function to health outcomes, particularly for valvular heart disease. Additionally, his research focuses on the optimal use and timing of cardiac imaging in practice. He specializes in the analysis of large administrative, registry, and clinical trial data, in particular imaging registries. He has received grant funding for this work from the American Heart Association and the National Institutes of Health and he has published more than 60 peer-reviewed publications in journals such as Circulation, European Heart Journal, and the Annals of Internal Medicine. He serves as a guest editor and Editorial Board member for the Journal of the American Society of Echocardiography and is a member of the ACC Imaging Council Leadership committee. Dr. Strom was a member of the inaugural class of the American Society of Echocardiography’s Leadership Academy and is the inaugural member elected to the ASE Board of Directors in this capacity. In addition to his role as Co-Chair of the Image Guide Echo Registry committee, he serves as the ACC representative to the board of directors of the Joint Review Committee on Education in Diagnostic Medical Sonography (JRC-DMS) which oversees training in diagnostic medical sonography in the US, the ACC Commissioner to Commission on Accreditation of Allied Health Education Programs (CAAHEP), the largest programmatic accreditor of the health sciences professions, accrediting over 2,100 education programs in 32 health sciences occupations, and is a member of the Board of Directors of the International Contrast Ultrasound Society (ICUS).

Close

James D. Thomas

Dr. James D. Thomas is a cardiologist at Northwestern Medicine with a clinical focus in valvular heart disease and echocardiography and extensive research into applying physical principles and advanced technology in cardiovascular imaging. He now serves as Director for the Center for Heart Valve Disease and Academic Affairs in the Bluhm Cardiovascular Institute and co-directs the Center for Artificial Intelligence in Cardiovascular Disease while serving as Professor of Medicine at Northwestern University Feinberg School of Medicine.

Born and raised in Oklahoma City, Dr. Thomas attended Harvard College (graduating summa cum laude in Applied Mathematics) and Harvard Medical School before clinical training at Massachusetts General Hospital and the University of Vermont. Dr. Thomas has over 650 peer reviewed publications with an h-index of 149. He is past president of the American Society of Echocardiography (ASE) and co-chairs a committee to standardize the measurement of myocardial strain by echocardiography. He previously served on the Cardiovascular Board of the American Board of Internal Medicine (ABIM) and as co-chairman for the 2007 American College of Cardiology (ACC) Annual Scientific Sessions.

Dr. Thomas also serves as lead scientist for ultrasound with NASA, focusing on the effects of space on cardiovascular function. Other research interests include cardiac mechanics, application of new echocardiography technology, artificial intelligence and integration of engineering principles into clinical decision-making.

Close

Andrew Grover

Andrew Grover brings 25 years’ experience in growing successful businesses across a diverse range of industries. As a founder and investor in numerous innovative companies, his businesses have been featured in BRW Fast 100 and Deloitte’s Fast 50 over several years.

Close

Jessamyn Lyons

Jessamyn (Jess) Lyons is a Chartered Secretary, a Fellow of the Governance Institute of Australia and holds a Bachelor of Commerce from the University of Western Australia with majors in Investment Finance, Corporate Finance and Marketing. Jess is a highly experienced Company Secretary and has held positions with Macquarie Bank, UBS (London) and Patersons Securities.

Close

Steven Formica

Steven Formica brings to the company significant business management and development experience. He has led a number of privately held business ventures across multiple industry sectors. Mr. Formica is currently the non-executive chairman of ASX listed Ragnar Metals (ASX:RAG), non-executive chairman of ASX listed Albion Resources Ltd (ASX: ALB), non-executive chairman of ASX listed Kaiser Reef Limited (ASX: KAU), non-executive director of ASX listed Bindi Metals (ASX:BIM), non-executive director of ASX Listed Great Northern Minerals Limited (ASX: GNM), and a successful investor in a number of ASX listed entities. Mr. Formica has previously held directorships with ASX listed companies Jade Gas Holdings (ASX:JGH), Labyrinth Resources Ltd (ASX: LRL), Bowen Coking Coal Ltd (ASX: BCB) and Lindian Resources Limited (ASX:LIN).

Close

Steve Picton

Steve Picton is an experienced Board Director and business leader. As CEO of mobile virtual network operator goTalk Limited, he increased revenues to more than $100M. Mr. Picton holds a Bachelor of Science in technology and a Master of Science (Business) from London Business School and is both a Chartered Engineer and a Member of The Institute of Company Directors. He is also a Sloan Fellow which was awarded to him in 1993 by the Sloan Foundation as part of the joint MIT, Stanford and LBS programme. Mr Picton is currently the non-executive chairman of ASX listed FlexiRoam Ltd (ASX: FRX).

Close

Ken Nelson

Ken Nelson is a leading US-based medical technology and healthcare executive with over 20 years’ industry experience. During his career he has been pivotal in leading successful commercialisation efforts with multiple cardiac-focused digital health companies including remote cardiac and diagnostics monitoring business, BioTelemetry, wearable device company, iRhythm and ambulatory ECG solutions monitoring group, Bardy Diagnostics. Currently, he serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator (www.medtechinnovator.org), the largest medical technology and digital health startup accelerator globally.

 

In addition to this, Ken serves as Chairman to the Board of Israeli-based medical technology company, CardiaCare, and is an active Board member of other cardiac-focused digital health and medical technology companies including HeartBeam (NASDAQ: BEAT), Acarix (NASDAQ: ACARIX), US-based company Epitel, and European-based platform Happitech. Ken also sits on a number of advisory boards and planning committees for early-stage medical technology companies, as well as several industry groups including the Innovation Advisory Board of Heart Rhythm Society, the Health Tech Innovation Business Advisory Board and the Heart & Brain Accelerator of the American Heart Association.

Close

Partho P. Sengupta

Dr Partho P. Sengupta is the Henry Rutgers Professor and the Chief of Division of Cardiology at Rutgers Robert Wood Johnson Medical School & University Hospital. Dr Sengupta completed his clinical residency and cardiology fellowship at Mayo Clinic Rochester and Arizona respectively. He has over 250 peer-reviewed publications.

Prior to joining Rutgers, he served as Abnash C. Jain Chair and Professor of Cardiology and the Chief of Division of Cardiology and Director of Cardiac Imaging at West Virginia University, Morgantown. He is an Associate Editor for the Journal of American College of Cardiology: Imaging and has served as a member of the Board of Directors for the American Society of Echocardiography and as the Chair of the ASE Telehealth and New Technology Taskforce.

He has won several excellence awards including ASE’s Young Investigator’s Award in 2004, Mayo Clinic Research Award in 2007, Mayo Brothers Distinguished Fellowship Award in 2009, AACIO Young Investigator Award in 2010 and ASE’s Rich Popp Award for excellence in Teaching in 2020. He also received ASE’s 14th Feigenbaum Lectureship for recognizing his significant contributions to research in the field of echocardiography. He delivered ASE’s first-ever presentation using hologram technology at ASE’s 24th Annual Scientific Sessions.

His futuristic ideas, investigative skills and international work have been widely acclaimed by major media outlets and he was an invited stage speaker for TEDMED 2016. He has been nominated by the American Medical Association for “Inspiration in Medicine” talk for the year 2017.

Close